A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression
ID Number 16-1422Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called nivolumab in combination with brentuximab vedotin. Nivolumab is an antibody that is being tested to see if it will allow the body's immune system to work against tumor cells. Brentuximab vedotin is an antibody-drug conjugate. The antibody part of the drug binds to CD30 which often occurs on diseased cells but rarely on normal tissues.
Recruiting Patients: Yes